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on the presence of symptoms (group A: 8 asymptomatic pts and group
S: 7 symptomatic pts). We compared pulse pressure, cerdiothoracic ratio
(CTR), echocardiographic variables (LVDd, LVDS, FS, LAD), plasma ANP
and BNP levels between the two groups. The plasma ANP and BNP levels
were significantly higher in group S than in group A (107.1 + 35.6 vs. 21.4
& 10.8 p~ml, p <0.05, and 356.0 + 172.2 vs. 56,5 + 34.8 pglml, p <
0.05, respectively). In group A, only one patient showad an abnormal high
level of ANP (> 40 p~ml) while all pts showed abnormal high level of BNP
(> 20 pglml). On the other hand, all pts in group S showed abnormal high
levels of both ANP and BNP. And pulse pressure, CTR, LVDd, and LVDS
in group S were significantly increased than those in group A. Pulmonary
capilla~ wedge pressure and left ventricular end-diastolic pressure were
also elevated in 4 of 5 symptomatic pts performed cardiac catheterization.
These findings suggest that the elevated plaama ANP level indicates the
decompensated state of Ieftventricle and that plasma BNP level is increased
not only in symptomatic pts but also in asymptomatic pts with chronic AR
according to its severity. Conclusion: The measurement of plasma ANP and
BNP levels is practical in the evaluation of chronic AR.
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AM reduces the blood pressure, pulmonary vascular resistance, and in-
creases pulmonary blood flow. Recent reports showed that AM mRNA and
and AM receptor mRNA is strongly expreased in the lung. To determine
the pathophysiological aignificence of AM in the pulmonary circulation, we
investigated the relationship between plasma levels of AM and pulmonary
hypertension in patients with MS. Plasma levels of AM in blood samples ob-
tained from the vein, pulmonaty artery, left atrium, and aorta were measured
by RIAin 23conaecutive patients with MS (53 + 10yrs)who were undergoing
percutaneous mitral commissurotomy. Patienta with MS had higher venous
plasma levels of AM than age-matched normal controls (3.9+ 0.3 vs. 2.5+
0,3 pmol/L, p < 0.01). There was a reduction of plasma AM levels from the
pulmonary artety to the left atrium (3.8+ 0.2 vs. 3.2+ 0.4, p < 0.01). These
levels significantly correlated with mean pulmonary artery pressure, total pul-
monary vascular resistance, and pulmonaty vascular resistance (r = 0.65, r =
0.63, r= 0.65, eech p < 0.01). Multiple regressionanalysis revealedthat total
pulmonaty vascular resistance independently mrrelated with plasma levels
of AM (p < 0.01). Given that the vascular wall mainly produces AM, and that
AM specific receptors exiat on the smooth muscle cella, and that AM acta on
the pulmonary vascular bed, increaaed plaama AM in patients with MS may
help to prevent the increase in pulmonary arterial resiatence in secondary
pulmonary hypertension.
m108542 “NeturelHistories”of MitralValveProlapse
A. Zuppiroli, F. Mori, S. Favilli, F. Pleri, V. Troiani, M. Bini, A. Dolara,
M.J. Roman M.J. O’Gradyl, R.B. Devereuxl. U.O. Cardiobgia 2,
Ospedale Careggij Fhrze, Ita& 1Cornell Medicai College, New York,NY
USA
The prognoais of mitral valve prolapse (MVP) remains uncertain, as previous
longitudinal studies of patienta (pts) with MVPgiveeatimatesof the incidence
of complications from 0.3 to 3.7/100 patient-years (p-yre). Between January
1979 and August 1996 a total of 263 pts, aged 43 + 19 yeare, 140 (53%)
women were followed for a mean of 96 months in a referral center for
valvularheart diseaaea.During the follow-up periodatotal of 63mmplications
occurred (3.0/100 p-yre): 46 pts (2.2/10Qp-yre) required mitral aurgery, 10
auffered cardiac death (0.5/100 p-yrs), 6 developed necrologic ischemia
(0.3/100 p-yrs) and 1 developed infective endocarditis (0.04/100 p-yrs). The
overall rate of complications varied aignificently (all p < 0.0001) in relation
to demographic, clinical and echocerdiographic variables, being higher in
men (odds ratio [OR] = 2.0), in subjects ? 45 yrs (OR = 9.5), in those with
a holosyatolic murmur (OR = 25.4), in those with enlarged (Z 60 mm) left
ventricle (OR = 12,5) or left atrium (z 40 mm) (OR = 29.2), in those with
a grade 3 or 4 mitral regurgitation (OR = 33.6) and lower in those with an
audible midsystolic click (OR = 0.07). This rate of complications far exceeds
the 1/100 p-yre we previously reported in a series of relatively unselected
pts or family members in New York, but predictors of complications are quite
eimilar. Therefore it ia confirmed that in a common entity like MVP tettiary
csrecenters mainly seethe most affected individuals: this selection bias adds
to male gender, older age and markers of mitral regurgitation in predicting an
adverse “natural hiatory” of MVP.
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There is very Iittledata on theelectmphysiologic mechanisms and subatratea
for ventricular techycerdia (VT) among petienta with valvular heart diaease.
We analyzed the mechanism of inducible sustained monomorphic VT in pta
with valvular hearl disease. There were 27 pts (23 men, 4 women) age 60
+ 15 yrs. in 10 of the 27 pts sustainad bundle branch reentty (BBR) was
the only mechanism of VT and 17 pts had intramyocardial VT (MVT). Both
groups were compared.
BBR (10) MVT (17) P VALUE
1. Age 5s * 19 60+ 1S ns
2. Cardiac Arrest 4 5 ns
3, Syncopelpresyncope 3 s ns
4. CAD 2 9 ns
5. EF > 55”/Q 4/10 1/17 <0.05
6. HV Interval (ins) 65& 15 56* 14 <0.01
Conclusion: In pts with valvular heart diaease: 1) Sustained BBR is the
mechanism of VT in approximately a third of the pts with inducible auateined
VT, 2) LV function was better preserved among pte with BBR compared to
MVT,and 3) HV interval is significantly prolonged in pts with BBR compared
to MVT.
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The natural history of mitral valve prolapse (MVP) was assesaed in 404 pre-
dominantly male, largely asymptomatic military members. Individuals had
auscultatory MVP by two cardiologists and/or echocerdiographic MVP by 2-
D imaging. There were 395 (98%) men and 9 (2%) women. Aaymptomatic
individuals discovered by routine screening numbered 161 (40%), whereas
243 (600A)were cardiovascular (CV) referrals. The ages ranged from 21 to
64years (mean =36 years). Follow-up time averaged 8.6 years (1-21 yeara).
During follow-up, 5 patients died, 3from non-cardiac causes, 5required mitral
valve surgery, 4 experienced cerebral iechemic events, 7 progressed to se-
vere MR, 10 had epiaodes of atrial fibrillation, and 8 had SVT greater than 15
seconds. There were no episodes of endoearditis or ventricular techycerdia
(> 15sec). SBEprophylexis was reported in77%of individualabysurvey. The
overall rate of significant complications was 0.92%/year. Stepwise Icgiatic re-
gression seleeted left ventricular enlargement (LVE) >6 cm (adjusted cdda
ratio (OR) = 7.7, p < 0.001), left atrial enlargement (LAE) >4 cm (adjuated
OR=4.3, p= O.004),and age> 45 yeara (adjueted OR= 3.2, P= O.015)to be
significant predictors of complications. in univariate analysia, additional rkk
factors of mitral valve thickening with prolapse and CVreferrala both hadodda
ratios significant top <0.05. Conclusion: The riak of complications with MVP
in an asymptomatic, male population is low. Significant risk factors include
LVE, IAE, and age >45 years Risks also appear higher for thoee referred
for CV diagnosis and those with both mitral valve thickening and MVP on
echocerdiogram. Auscultatory MVP was not a significant risk factor.
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